Swiss National Bank Sells 34,000 Shares of Elevance Health, Inc. $ELV

Swiss National Bank trimmed its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 5.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 651,300 shares of the company’s stock after selling 34,000 shares during the period. Swiss National Bank’s holdings in Elevance Health were worth $210,448,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Physician Wealth Advisors Inc. raised its position in Elevance Health by 331.6% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Activest Wealth Management boosted its position in Elevance Health by 66.7% in the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 34 shares during the last quarter. Rossby Financial LCC boosted its position in Elevance Health by 110.0% in the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock valued at $28,000 after buying an additional 44 shares during the last quarter. Vermillion & White Wealth Management Group LLC increased its stake in shares of Elevance Health by 94.9% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after buying an additional 37 shares during the period. Finally, BOK Financial Private Wealth Inc. bought a new stake in shares of Elevance Health during the second quarter worth $32,000. Institutional investors and hedge funds own 89.24% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ELV shares. Truist Financial cut their price target on Elevance Health from $400.00 to $390.00 and set a “buy” rating on the stock in a research note on Monday, February 2nd. Leerink Partners boosted their price objective on Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a report on Thursday, January 29th. TD Cowen restated a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research note on Thursday, January 29th. Finally, Royal Bank Of Canada cut shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target for the company. in a research report on Tuesday, February 3rd. Twelve research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Stock Performance

ELV stock opened at $280.80 on Tuesday. The business’s 50-day moving average price is $343.29 and its two-hundred day moving average price is $335.14. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a market cap of $61.98 billion, a PE ratio of 11.18, a P/E/G ratio of 1.60 and a beta of 0.51. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, research analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 2.5%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is presently 27.23%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.